Advertisement
Goldman, Sachs & Co. is acting as the sole book-running manager of theoffering. Deutsche Bank Securities Inc. is acting as co-lead manager and CIBCWorld Markets Corp. is acting as co-manager of the offering.
Advertisement
These shares are being issued pursuant to an effective shelf registrationstatement. This press release does not constitute an offer to sell or asolicitation of an offer to buy nor will there be any sale of these securitiesin any state or jurisdiction in which such offer, solicitation or sale wouldbe unlawful prior to registration or qualification under the securities lawsof any such state or jurisdiction. The offering is being made only by meansof a prospectus, including a prospectus supplement, forming a part of theeffective registration statement. Printed copies of the final prospectussupplement and base prospectus relating to the offering may be obtained, whenavailable, from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 BroadStreet, New York, New York 10004, Fax: 212-902-9316 or Email [email protected]). InterMune intends to file a final prospectussupplement relating to the offering with the SEC, which will be availablealong with the base prospectus filed with the SEC in connection with the shelfregistration on the SEC's website at http://www.sec.gov/.
About InterMune
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.
Forward-Looking Statements
This press release contains forward-looking statements, includingstatements relating to InterMune's expectations regarding the completion ofthe public offering. These statements are subject to significant risks anduncertainties, actual results could differ materially from those projected andthe company cautions investors not to place undue reliance on theforward-looking statements contained in this release. These risks anduncertainties include, without limitation, risks and uncertainties related tosatisfaction of customary closing conditions related to the public offering.There can be no assurance that InterMune will be able to complete the publicoffering on the anticipated terms, or at all. If InterMune is unable to raiseadditional capital when required or on acceptable terms, it may have tosignificantly delay, scale back or discontinue one or more of its drugdevelopment or discovery research programs. Additional risks anduncertainties relating to InterMune and its business can be found in the "RiskFactors" section of InterMune's preliminary prospectus supplement related tothe public offering filed with the SEC on September 18, 2007. InterMuneundertakes no duty or obligation to update any forward-looking statementscontained in this release as a result of new information, future events orchanges in InterMune's expectations.
SOURCE InterMune, Inc.
